Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

Compounding that statistic, prior studies indicate some trans people at high risk for HIV transmission are hesitant to take ...

Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...

UCSF researchers have found a treatment for HIV that shows potential as a long-term solution for the chronic disease that, up until this point, has been held at bay in patients through a lifetime ...

Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The ...

A new study from UC San Francisco shows it may be possible to control HIV without long-term antiviral treatment—an advance that points the way toward a possible cure for a disease that affects 40 ...

A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda. A multi-national, ...

Over time, clonal expansion leads to an increase in the frequency of infected cells in a patient. The proviruses in daughter ...

HIV treatment has significantly evolved over the past 30 years, transforming HIV from a fatal disease to a manageable chronic condition. Despite advances, challenges remain in treatment access, stigma ...

The tools to stop the spread of HIV are readily available, but experts said they're not getting to the right people.

Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people ...